Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Pasteur
About this trial
The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group.
For this purpose:
* Patients with pre-existing gastric lesions will be invited to participate to this study. If they are willing to participate an additional blood sample (9 mL) will be collected at the time of the blood collection performed during their routine care * Healthy subjects will be invited to participate to constitute the control group. If they are willing to participate a blood sample (9 ml) will be drawn specifically for this study
Eligibility criteria
Qualifiers
18 years old or highter
written informed consent prior to any study procedure
Affiliated to a social insurance system
Untreated glandular atrophy (with or without intestinal metaplasia and/or dysplasia) and histologically diagnosed as of 2014
Disqualifiers
Autoimmune disease or disease that impacts the immune system (e.g: HIV)
Chronic inflammatory disease
Known evolutive cancer (excluding gastric cancer)
Treated in the last 3 months or currently treated with therapy that interferes with the immune system (e.g. immunosuppressive therapy)
Trial design
Treatments tested in this trial
- Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine care.
- Blood collection
Treatment groups
2,500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Institut Pasteur
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborator
Source ClinicalTrials.gov